#MSParis2017 – Tysabri Did Improve Walking and Hand Function in Failed SPMS Trial, Researchers Say
News
While Tysabri (natalizumab) failed to slow worsening disability in people with secondary progressive multiple sclerosis (SPMS) in a Phase 3 trial, researchers now suggest that the ... Read more